Pharmaceuticals, Biotechnology and Life Sciences
Halozyme Therapeutics said Wednesday that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.
ImaginAb has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.
Revenues increased approximately 19.5% to €35.2 million, compared with €29.5 million during the same period last year.
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
Contained and sterile transfer solutions expert, ChargePoint Technology, has appointed Stephen Eastick as UK Sales Manager.
Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).